-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Hepatitis B virus (HBV) is an important cause of chronic liver disease.
Hepatitis B virus (HBV) is an important cause of chronic liver disease.
In a meta-analysis, researchers found that even with the currently approved oral nucleoside analogues for the treatment of HBV-Entecavir (ETV) or Tenofovir Disoproxil fumarate (TDF), the treatment After 48 weeks, only a similar HBeAg seroconversion rate (10% VS 16%) was produced, which means that despite the use of nucleotide analogs, most patients have not undergone hepatitis B surface antigen seroconversion.
immunity
Researchers conducted this trial on HBeAg-positive patients who had received antiviral therapy for more than 1 year.
Two groups of patients: the median age of the FMT group and the AVT group were both 29 years (P = 0.
This study confirmed that FMT appears to be safe and potentially effective in terms of viral suppression and HBeAg clearance in HBeAg-positive CHB patients, but it still cannot replace drug therapy.
This study confirmed that FMT appears to be safe and potentially effective in terms of viral suppression and HBeAg clearance in HBeAg-positive CHB patients, but it still cannot replace drug therapy.
Original source:
Ashish Chauhan.
springer.
com/article/10.
1007/s10620-020-06246-x" target="_blank" rel="noopener">Fecal Microbiota Transplantation in Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients: A Pilot Study.
Leave a message here